No—Corrective Insulin and Sliding‑Scale Insulin Are Not the Same
Corrective (or "correction") insulin is a supplemental dose given in addition to scheduled basal and prandial insulin when pre‑meal glucose exceeds a predefined threshold, whereas sliding‑scale insulin (SSI) is a reactive‑only regimen that provides no scheduled basal or prandial coverage and is explicitly condemned by all major diabetes guidelines as monotherapy.11
Key Distinctions Between Corrective Insulin and Sliding‑Scale Insulin
Corrective Insulin (Appropriate Use)
- Corrective insulin is administered as a supplement to a scheduled basal‑bolus regimen—never as a replacement for basal or prandial insulin.11
- A simplified correction protocol adds 2 units of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL and 4 units for glucose > 350 mg/dL, given in addition to the patient's scheduled prandial dose.11
- Individualized correction doses can be calculated using the insulin sensitivity factor (ISF): ISF = 1500 ÷ total daily insulin dose; correction dose = (Current glucose – Target glucose) ÷ ISF.1
- Correction insulin addresses acute hyperglycemic excursions and does not accumulate to steady state, so it can be adjusted independently of basal and prandial components on their respective schedules.2
Sliding‑Scale Insulin (Condemned Practice)
- SSI consists solely of reactive rapid‑acting insulin doses given after a high glucose reading, with no scheduled basal or prandial insulin.11
- SSI treats hyperglycemia reactively rather than preventing it, leading to wide glucose fluctuations that worsen both hyper‑ and hypoglycemia.113
- Only ≈38 % of patients achieve mean glucose < 140 mg/dL with SSI alone, versus ≈68 % when a scheduled basal‑bolus regimen is used.114
- The American Diabetes Association and all major diabetes guideline societies explicitly condemn SSI as monotherapy, recommending immediate discontinuation in favor of scheduled basal‑bolus therapy.1156
Why Sliding‑Scale Insulin Fails
Lack of Basal Coverage
- SSI provides no basal insulin to suppress hepatic glucose production between meals and overnight, resulting in persistent fasting hyperglycemia.11
Absence of Scheduled Prandial Insulin
- SSI lacks scheduled prandial insulin, causing post‑prandial spikes that are later corrected with large reactive doses, creating a cycle of hyperglycemia → large correction → hypoglycemia → rebound hyperglycemia.113
Poor Clinical Outcomes
- SSI is associated with treatment failure (defined as > 2 consecutive glucose readings > 240 mg/dL or mean daily glucose > 240 mg/dL) in ≈19 % of patients, compared with 0–2 % in basal‑bolus regimens.4
- Sliding‑scale regimens are often left unchanged throughout hospitalization, even when glucose control remains poor.37
- Uncertainties or missing information related to execution, timing, glucose levels, or insulin dose are present in ≈30 % of all anticipated points of care involving SSI.7
- Appropriately timed, successive glucose measurements documented a decrement in elevated glucose to within target range after only 12 % of SSI injections; glucose levels remained elevated after 84 % of injections.7
Recommended Insulin Regimen Structure
All Insulin‑Requiring Patients Need Three Components
- Basal insulin (e.g., glargine, detemir, degludec) given once daily provides continuous background coverage and suppresses hepatic glucose production.115
- Prandial insulin (rapid‑acting analogs such as lispro, aspart, or glulisine) administered 0–15 minutes before each meal covers meal‑related glucose excursions.115
- Correction insulin is used only as a supplement to scheduled doses when pre‑meal glucose exceeds predefined thresholds.115
Initial Dosing for Hospitalized Patients
- Standard‑risk patients (insulin‑naïve or low‑dose home therapy): start with a total daily dose of 0.3–0.5 U/kg/day, allocating 50 % to basal (once daily) and 50 % to prandial (divided among three meals).115
- High‑risk patients (age > 65 yr, renal impairment, poor oral intake): use a lower starting dose of 0.1–0.25 U/kg/day to minimize hypoglycemia risk.115
Titration Protocols
- Basal insulin: increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL; increase by 4 U every 3 days if fasting ≥ 180 mg/dL, targeting 80–130 mg/dL.115
- Prandial insulin: increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose, targeting < 180 mg/dL.115
- Correction doses: use the simplified scale (2 U > 250 mg/dL, 4 U > 350 mg/dL) or the ISF calculation, always in addition to scheduled doses.11
When SSI Might Be Acceptable (Very Limited Circumstances)
- SSI as monotherapy may be appropriate only for:
- Patients without pre‑existing diabetes who develop mild stress hyperglycemia during hospitalization.6
- Patients with well‑controlled type 2 diabetes (HbA1c < 7 %) on diet alone or minimal oral therapy at home who have mild hyperglycemia.6
- Patients who are NPO with no nutritional replacement and only mild hyperglycemia.6
- Patients who are new to steroids or tapering steroids.6
- In all other scenarios, SSI should be immediately discontinued and replaced with a scheduled basal‑bolus regimen.1156
Safety Considerations
Hypoglycemia Management
- Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed.115
- If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration.115
Critical Pitfalls to Avoid
- Never use rapid‑acting insulin at bedtime as a sole correction dose, because this markedly increases the risk of nocturnal hypoglycemia.115
- Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin when frequent corrections are needed.115
- Do not continue SSI unchanged throughout hospitalization when glucose control remains poor.37
Expected Clinical Outcomes
- With a properly implemented basal‑bolus regimen that includes corrective doses as needed, ≈68 % of patients achieve mean glucose < 140 mg/dL, compared with ≈38 % using SSI alone.114
- Basal‑bolus therapy does not increase overall hypoglycemia incidence relative to inadequate SSI approaches when properly titrated.114
- Treatment failure (> 2 consecutive glucose readings > 240 mg/dL) occurs in 0–2 % of patients on basal‑bolus therapy versus ≈19 % on SSI alone.4